Fakih et al. reported that upregulation of certain genes related to immune sensitivity, including allograft rejection, interferon γ response, IL-6/JAK/STAT signaling and interferon α response, was associated with an improved clinical outcome in pMMR colorectal cancer treated with nivolumab plus regorafenib [15]. This evidence concerns the gene SOAT1 and colorectal cancer.